programs R&D give our CBXXXX clinical now our on I'll brief update Steve. beginning Thanks a program. with
please. slide Next
stage MOTS-c colleagues. of NASH Phase analog enhanced potential a is novel currently co-founder a as our naturally of placebo appropriate of and clinical Ib Ia/Xb treatment Dr. is dose, occurring dose Cohen CBXXXX discovered his controlled, dose a CBXXXX tolerability, in the The most blind ascending peptide testing in study our is adults to Ia involved by Phase Hussey double mitochondria assessment and complete and for obesity. encoded sending stage. for and healthy the select Phase the safety pharmacokinetics single multiple
MRI-PDFF No in Changes various the by baseline. phase fat Phase The effects of that of a XX% once at potential daily on observed all are is subjects issues the were biomarkers controlled study. NASH, obese have is must relevant be of assess Phase given This Ia double to designed will in in minimum CBXXXX restarting of significant NAFLD. tolerability and weight, body placebo Ib CBXXXX a assessed and fat, safety study liver or disease. part and to level evaluation blind obesity subjects after of liver the one dose metabolic fat the liver with
announced Ib been we in paused as XXXX As have by study more studies pandemic, is globally pause have of to affected the due March, the to currently This unique and many than COVID-XX. the not CohBar, stage is of paused clinical enrollment. them Phase
status. As change year sites expect enrollment. update earlier clinical in call, we the last this new to added and monitor a accelerate We're the provide study there's the we to to situation mentioned to continuing order on an once in three quarterly
subject-by-subject But be as providing enrollment. will not on previously details stated we
this unable that COVID-XX guidance the provide is on we're pause at lifted, the timing In line of of availability COVID-XX to the of top for data timeline result time. a the activity progress and the have post this the As study of more study event the the call. enrollment we COVID-XX resumes. on update will rate on to be function on plan next investor a We clarity the that will when pause
slide please. Next
months. our the the next to three Turning of six rest programs expect over additional data to we pipeline, from several
On the optimization last peptide on quarterly four stage. preclinical call, we in the shared programs information
and CXCRX, The inhibitors our marrow. immune that localization cancer first cells of Type a CXC bone tumors analogs that was Chemokine as in other January are announced of in well as potent the X indications. for highly family metastasis receptor the key selective regulates a MBTX within of of of or Receptor these analogs the peptides growth and MBTX are the chemokine
family the in MBTX a additional to melanoma, the analog stem successful vitro we peptides and mobilization, last enhanced to cell and advancement. of where We plan goal an In vivo based setting shared now the of haematological of On the candidate efficacy call, in including data advance identifying cell this translation a assays models, program preclinical mouse models for on this cancer the activity of of chemotherapy. aggressive in model of into with potentially
In The Society, program in acceptance We of this American or our MBTX IPF. abstract at MBTX efficacy data meeting. second The late diseases. fibrosis models we April our program of peptides of idiopathic breaking for the on the is on analog enabling in of the Thoracic ATS fibrotic identifying and for studies COVID-XX, national therapeutic person expanded concerns ATS meeting mouse previously a planned prophylactic pulmonary shared been now to meeting they're has family by peptides cancelled goal with advancement virtual a has IND was originally around abstract May later we're studies. the ATS further for additional eventually been this due of and This towards running candidate year. and published considering but announced
to a program, program of effects. for vitro immune enhancing look human vivo advancing will with previous in family is these cells of cells be potential cancer in the vitro. peptide cancer immunotherapy, on in also The translation into studies That the third of MBTX killing calls discussed analogs by
COVID-XX. family on ARDS On have model program X a associated Respiratory the This that has The this target including mouse indication. Distress final specifically positive analogs. already program with or apelin is results I include newest indication, shown expanded is list CBXXXX the a been to novel will now of a focus new call, This ARDS diabetes. of Acute agonists today's Type on Syndrome in
please. slide, Next
analogs, for ARDS. Acute Respiratory target CBXXXX and COVID-XX this Syndrome Distress or the a ARD, associated So new specifically our is
Next with what Well, understanding ARDS let's start slide please. is.
what lungs, seeing a a viral can infections, heart now injuries is confusion, as fast triggered sepsis, chemicals by traumatic bigger influenza much as viral or presents are other most of breath, of rapid and oxygen shortness be of mental just in rate, ARDS to we accompanied a blood such COVID-XX. the low infection, injury, including inhalation and of sudden So smoke sources. breathing, tiredness. or ARDS ARDS by problem extreme variety commonly setting than the bacterial
there right the where lining sacs, lung occurs. lungs and to of proteins that is out oxygen. is separates flow from fills damage entering intense layer blood of and that of involves that send When thin sacs Cells an lungs exchange air slide, the that dioxide As or and the the shown blocks the carbon inflammatory absorb cells oxygen damaged, ability a the response. of air blood Blood alveoli capillary damaged the signals a leakage of on of to blood from thin gradually of the ARDS fluid, the the the start the cascade cells alveoli
injury. cause morbidity usually and patients seven to hospitalized major occurs other within ARDS of mortality are for is about Now and days XX reasons who the among initial a of
care care, There reduce pain for with patients levels and rehabilitation oxygen effective infection, in ventilation to to hospital leads management inflammation, reduce breathing, attempt are mechanical The blood costs. for COVID-XX without quality no for treated long improve time unmet intensive with spent of need reduce or supportive about There and healthcare to are million effective treatment drugs is of a ventilators, need resulting major need and low convalescence life. Even support anxiety. prevention ARDS ARDS, instead and a and people expensive on safe and medical ARDS are globally. reduce the is rising mortality major unmet to a three affecting a and to that contributor stays huge
of Next many severe the cells slide the of ARDS coronavirus In is up COVID-XX, in the alveoli. consequences this why cellular ventilators. membrane of infection, fluid has so air to the capillary accumulation the infects local setting emerged people the the leads inflammation, lethal leakage one please. separates that from on cases, the blood of virus most lining that resulting In The of vascular spaces. leading as in damage and lungs, the thin alveolar destruction, the and pneumonia, to end loss
lungs the the blood and pump fluid, through saturated absorb harder with As heart must the fill cannot blood oxygen enough to the lungs. force
potentially results effect heart, This where signals of multi eventually storm the devastating also a but liver dysregulated the Another and is damage the in the inflammatory in inflammation, the brain, and cellular failure. release inflammation other called virus a intense organs local kidneys, storm. like cytokine of organ result the reaches can
Next slide please.
that dysfunction of major lethal shows of presence and is of severe disease a consequences. diabetes like factor The increase the evidence and Now, all contributing chances the severity recent COVID-XX. metabolic comorbidities underlying hypertension, to obesity,
recent on COVID-XX. of with need fate As had a medical impact presence The X,XXX ventilation, to at the overall prior overall infection, for survival. patients including a significant look X an the increased took intervention, a example, publication retrospective and of diabetes Type
a controlled only diabetes the left, those for chance much COVID closer as of patients with levels. patients comorbidity on well those had control a diabetes greater XX% with In died, of fact, die. diagram And dying, shown looking X.X% in X% of those sub-population just poor had this of glucose glucose X.X% who the the to versus at with without while
Next slide, please.
adipocytes variety activating cell functions, inflammation peptide fluid processes. apelin occurring a signaling by surface APJ how Apelin cells homeostasis, and but a including apelin at particularly homeostasis, abundant figures regulate to in a heart. and other cardiovascular It metabolic is receptacle into the most broadly picture. tissues, It's lung let's receptor biological this in or function, works by signaling of Now look adipokine. fat secreted or cell a naturally found
important involving pathways of turn surface of you other the or therefore control key regulate on Ras, signaling of ERKX/X, AMPK, that a system effects. slide, leading the expression the different leads and eNOS in a cells, Apelin right of this broad others. These regulators of pathways proteins. several On like activation the include stimulation pathways and of see, regulatory to receptor to is multiple regulator pleiotropic intracellular
broad acute or including ARDS, or have like in to damage in acute injury, shown models lung toxins models of acid chemical protective caused bacterial edema been and of the has reduction by in prevention Apelin like accumulation or fluid effects rodent animal cells Lipopolysaccharide lung of LPs. of pulmonary oleic
protects from levels beneficial such and fat Importantly, pro-inflammatory also in cytokine Apelin and obese apelin metabolic has mice. by body also signaling shown decreasing similar in damage. weight deposits the as cells organs, other liver decreases these effects
the is minutes. However, in is metabolized about and rapidly apelin only itself vivo half-life eight
of is for the this itself the So peptide in too clinic. short use effective
Next slide please.
year. same itself. the shared been in CBXXXX analogs magnitude that the peptides a these last that plasma of the at them cases, meeting We of family Now, in in human novel also X agonists vitro, using vitro. the natural Type different mitochondrial are this essay encoded previously stimulating the a for novel Diabetes in signal number diabetes by human apelin American Metabolic peptides peptide setting of in as a some within confirmed produced a on Association CohBar's receptor genome. activity of based stability family data demonstrated apelin of at We've of apelin agonist display formats, has
effects similar multiple ability apelin analogs apelin rodent Based XX the lung engage and to In obese to body presentation, No acute on day mice that observed XX CBXXXX that of issues studies been induced administration these have signaling believe injury. to mass. we weight of mice could date and the now in the CBXXXX reduced to to glucose on led their obese in poster showed diet potentially pathway, fat analogs have that to tolerance we safety improved molecules.
to Let's the go slide. next
signaling the analogue also that injury. lies the for with many are ARDS CBXXXX induced rationale pathway in regulate by the potentially animals COVID-XX COVID-XX using treat associated to a damaging apelin So of of in the processes to ability demonstrated
described, the vascular organ here coronavirus left producing damaging to we've storm leading of see pneumonia, cytokine low accumulation, the you blood same array already that fluid COVID-XX and effects failure. oxygen infection, leakage, the On multi
vascular you Next of processes events see effect could initiating reduce potentially protective many a to the receptor, And CBXXXX engaging the accumulation by the could slide, damaging and absorption there potentially a analogue By of analogue a here. block the series have please. CBXXXX that accumulation potentially leakage improve fluid levels the shown in and decreasing blood. oxygen fluid oxygen raise of apelin
cause of storm could the other of blocking of strains injury, potentially of to from future apelin failure, and independent after resulting organs could signaling consequences ARDS infections protect reduce health including By thereby cytokine other ARDS, effects recovery equally lung forms approach peptides the mortality this bacteria. Since and novel by the viruses long-term from the the be COVID-XX. applicable or are even from of
the now So underlying approach. that data some let's at support of look this
introducing toxin apelin Next the lung structure into in the animals you receptor one a case, inflammatory on figure into tissue, stimulating infiltration slide, data cells lung slide, the can this the In acute this the in injection preserved of reduced please. effects and injury. we injured example in the protective see setting see as the lung by just A. of bacterial of In published of the lungs, apelin
important apelin protein content leaking pro-inflammatory difference by the TNF-alpha, by the fluid decreased in secretion the of accumulation in as of three the B. the lungs water components fluid also C. reduced also Apelin measured figure lavage the figure measurement was such Capillary of leakage reduced apelin cytokines as based on in also the the of in And IL-X finally, and bottom storm. cytokine Bronchoalveolar the IL-X into figures beta, in
results this signaling summarize the studies stimulating published In in apelin please. obese pathway mice. we slide slide of Next of
multiple glucose uptake also of lead increasing fat had and in levels a storage to fatty apelin reduction of injection acids. insulin, weight metabolic on effects circulating Here, deposits. reducing effects These body and dysfunction, and muscle, into beneficial triglycerides
So animal comorbidity effects is on clear apelin significant a in protective ARDS. model, what this of had signaling
slide please. Next
analogs. the novel So own apelin we previously CBXXXX the now CohBar's let's shared at agonists data for have look
CBXXXX Our one receptors in very cell family action of of specific included radio revealed a of a the or this interaction on range the the poster analogs of APJ. exploration data XXXX receptor, activation surface broad of mechanism of between peptides, and selective apelin receptor new
the a in response As the the the maximum some shown similar in the black analogs bar. that peptide our receptor, at was the CBXXXX of blue maximum effect bars of novel on the left, figure natural produced apelin to
On the of ANP second that signaling. of characteristic CBXXXX see APL essay we the in cyclic overexpressing the analogs right, decrease cells a apelin production the receptor,
slide please. Next
the also shown in X to or analogs induced CBXXXX diabetes. human Now, of effects in beneficial model Type a DIO diet vivo were obese mice have
injection, indicating here, to improved of treated following reduced administration a in bolus top, As in levels and daily shown an peptide loss at on peak glucose produced weight the a CBXXXX the CBXXXX left glucose tolerance. challenge the of body with that, analogs animals. reduced several analogs study significant compared XX another dosed days glucose obese mice also once for and decreased Below the fatness vehicle
that the after was glucose also the two hours glucose bottom significantly in reflected levels lower effect right. on Now, blood shown challenge
demonstrate those obese So injection. these effects apelin mice by similar results to produced in
Next please. slide
and how we potential have ARDS believe of COVID-XX. summarize to to treat the specifically could back in cycle let's analogs more setting the now CBXXXX So ARDS
Here once produces. array the again COVID-XX that damaging is of processes
And let's vascular injury target protect and release viral apelin apelin insults. individual by caused Other the We leakage cytokine whether in signaling lung of the effects. receptor engaging please. the go drugs here COVID-XX issues. acute bacterial, signaling and injury, in cytokines animals that these to animal potential the damaging only chemical, CBXXXX down now subset We fluid know can shutting apelin from analog, other or a accumulation is next slide being models. now know and reduces And these to are the evaluated impact is the
to with apelin completely seen on block this the the important It's these the range is associated novel damaging of know observations, could based that injury. potentially pathway CohBar's So same COVID-XX effects of agonists of CBXXXX signaling ARDS. independent source
now And viral So include forward our moving have infections. potential associated of forms of ARDS, analogs ARDS. ARDS. COVID-XX We're utility in other could of future models in preclinical or this could for and CBXXXX evaluation CBXXXX analogs with bacterial
This models of to next respiratory moving related candidate final the the activities. year overview programs The of the in syndrome paused level first treating slide. and fibrosis forward a COVID-XX study and currently and clinical animal idiopathic clinical distress Let's this our the slide current testing from our R&D in with high IND we NASH CBXXXX, move shows awaiting potential cancer based programs enabling in therapeutic, mitochondria goal candidate our preclinical currently acute pulmonary next obesity. of identifying delay, is four have use Ib to clinical for resolution various for for advancement Phase
see additional provide our to call. we an next months preclinical the and on emerging three next We to on these update six to data programs expect in plan
with I'll to the back that, Steve. return And call
